UTIs and SGLT-2 inhibitors

Concerns have previously been raised in connection to the possible relationship between treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitor drugs (e.g. canagliflozin and dapagliflozin ) and risk for severe urinary tract infections (UTIs).Recently...

High risk of recurrent VTE after anticoagulants discontinued

Canadian researchers have recently published a systematic review and meta-analysis which examined the rates of symptomatic recurrent venous thromboembolism (VTE) following cessation of anticoagulant treatment for patients with a first unprovoked VTE. Analysis of 18...

Predicting fatal outcomes after drug-induced liver injury

A team of American researchers has recently examined the association between co-morbidity burden and outcomes in patients with drug-induced liver injury, developing a multiple logistic regression model to calculate risk of death inside of six months. The model...

RCTs don’t necessarily represent the wider population

A recent meta-analysis has investigated differences between dialysis-dependent participants in large, multi-centre randomised clinical trials (RCTs) and other people from the general population undergoing dialysis. Differences in age, comorbidities and mortality rate...

Making drug interactions relevant again

Prescribers can overlook important alerts because of common alert fatigue arising from a hail of false-positive drug-drug interaction (DDI) alerts. To make alerts relevant again, the development of more appropriate alerts is required. The potential for...